Anti-Human Claudin-18.2 Reference Antibody (GB7004-09, RUO) (HX126146)

Name: Anti-Human Claudin-18.2 Reference Antibody (GB7004-09, RUO)
Brand: abinScience
SKU: HX126146
Price: 370 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HX126146
種反応性	Human
アプリケーション	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG
クローンID	GB7004-09
生物学的活性	GB7004-09 exhibits superior binding affinity, antibody-dependent cell-mediated cytotoxicity, and complement-dependent cytotoxicity against CLDN18.2-expressing tumor cells [1]. CLDN18.
ターゲット	CLDN18.2, Claudin-18.2
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P56856-2
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	GB7004-09, GB700409, GB700409
背景	Claudin-18 (CLDN18.2) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. CLDN18.2 is the therapeutic target of zolbetuximab (Vyloy).
参考文献	1. Zhenhao Zhou. Abstract 340: Development of high affinity anti-CLDN18.2 antibody to treat gastric cancers. Cancer Res 1 July 2019; 79 (13_Supplement): 340. [HX126146]
注意事項	For research use only. Not suitable for clinical or therapeutic use.